Journal
ACS CENTRAL SCIENCE
Volume 7, Issue 4, Pages 594-602Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acscentsci.1c00080
Keywords
-
Categories
Funding
- Department of Health and Social Care (DHSC) [EP/R013756/1]
- International AIDS Vaccine Initiative (IAVI) - Bill and Melinda Gates Foundation [INV-008352/OPP1153692]
- IAVI Neutralizing Antibody Center through the Collaboration for AIDS Vaccine Discovery Grant - Bill and Melinda Gates Foundation [OPP1196345/INV-008813]
- National Institute for Allergy and Infectious Diseases through the Scripps Consortium for HIV Vaccine Development (CHAVD) [AI144462]
- University of Southampton Coronavirus Response Fund
- Bright Future Trust
- National Institute for Allergy and Infectious Diseases [AI150481]
- UK Wellcome Trust Investigator Award [206422/Z/17/Z]
- Wellcome Trust [095541/A/11/Z, NR18477, NR21005, NT21004, 203141/Z/16/Z]
- MRC
- BBSRC
- NIHR Oxford BRC
- Wellcome [090532/Z/09/Z]
- National Institute for Health Research Biomedical Research Centre Funding Scheme
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China [2018-I2M-2-002]
- EPSRC [EP/R013756/1] Funding Source: UKRI
Ask authors/readers for more resources
Vaccine development targeting the SARS-CoV-2 virus focuses on the S glycoprotein as the principal target of the neutralizing immune response. Adenovirus-vectored vaccines have shown effective processing and assembly of viral antigens, mimicking the observed SARS-CoV-2 virus, making them a promising platform for SARS-CoV-2 vaccines.
Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation, and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirm the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
